← Back to Search

Device

Accelerated TMS for Schizophrenia (ATP Trial)

Phase 1 & 2
Waitlist Available
Led By Roscoe O Brady, MD, PhD
Research Sponsored by Beth Israel Deaconess Medical Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up before treatment (baseline) and 1 week and 3 weeks and 24 weeks post treatment
Awards & highlights

Summary

This trial is to test if a more intense Transcranial Magnetic Stimulation schedule can effectively treat symptoms of psychotic disorders like schizophrenia.

Who is the study for?
This trial is for adults aged 18-65 with a diagnosis of schizophrenia, schizoaffective disorder, or at high risk for psychosis. Participants must be stable outpatients, fluent in English, and capable of completing study procedures without recent hospitalizations or medication changes.
What is being tested?
The trial tests the safety and effectiveness of an accelerated schedule of repetitive Transcranial Magnetic Stimulation (rTMS) to treat symptoms associated with psychotic disorders like schizophrenia.
What are the potential side effects?
Possible side effects from rTMS may include discomfort at the stimulation site, headache, lightheadedness, seizures in rare cases, and hearing issues if ear protection isn't used during treatment.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~before treatment (baseline) and 1 week and 3 weeks and 24 weeks post treatment
This trial's timeline: 3 weeks for screening, Varies for treatment, and before treatment (baseline) and 1 week and 3 weeks and 24 weeks post treatment for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Tolerability of accelerated TMS
Secondary study objectives
Change in auditory hallucination severity
Change in cerebellar-cerebral resting-state functional connectivity
Change in information processing speed
+1 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: repetitive Transcranial Magnetic Stimulation (rTMS)Experimental Treatment1 Intervention
repetitive Transcranial Magnetic Stimulation (rTMS) in a iTBS pattern to the cerebellum at 100% of resting motor threshold
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
repetitive Transcranial Magnetic Stimulation (rTMS)
2014
N/A
~510

Find a Location

Who is running the clinical trial?

Beth Israel Deaconess Medical CenterLead Sponsor
848 Previous Clinical Trials
12,930,084 Total Patients Enrolled
22 Trials studying Schizophrenia
2,251 Patients Enrolled for Schizophrenia
Roscoe O Brady, MD, PhDPrincipal InvestigatorBeth Israel Deaconess Medical Center

Media Library

repetitive Transcranial Magnetic Stimulation (rTMS) (Device) Clinical Trial Eligibility Overview. Trial Name: NCT05567848 — Phase 1 & 2
Schizophrenia Clinical Trial 2023: repetitive Transcranial Magnetic Stimulation (rTMS) Highlights & Side Effects. Trial Name: NCT05567848 — Phase 1 & 2
repetitive Transcranial Magnetic Stimulation (rTMS) (Device) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05567848 — Phase 1 & 2
Schizophrenia Research Study Groups: repetitive Transcranial Magnetic Stimulation (rTMS)
~2 spots leftby Jan 2025